Kelly Blackburn
Executive Vice President of Clinical DevelopmentMs. Kelly Blackburn, MHA, served as Senior Vice President of Clinical Development at CervoMed Inc. (Formerly, EIP Pharma, Inc.) since joining in May 2018 and serves as its Executive Vice President of Clinical Development since April 16, 2025. She served as Clinical Consultant at aTyr Pharma Inc. since July 1, 2016. Ms. Blackburn served as a Vice President of Clinical Affairs at aTyr Pharma Inc. from July 2013 to July 1, 2016. Ms. Blackburn has experience in managing and leading clinical programs, including the development of innovative molecules for rare diseases. She served as the Vice President, Clinical Development Operations at Vertex Pharmaceuticals where she was responsible for the operational plans and strategy for the full product portfolio including two transformational programs, Kalydeco Incivek®. Prior to Vertex, she was director, Clinical and Safety Operations at Millenium Pharmaceuticals, where she was operationally responsible for the lead product, VELCADE®. Previous to that, she held several clinical operations roles of increasing responsibility at Vertex, Genetics Institute and Bayer Corporate. Ms. Blackburn received her B.S. in biochemistry from University of New Hampshire, MHA from Quinnipiac University and M.Ed. from Cambridge College.
Positions
- Company NameCervoMed Inc.Stock CodeCRVOPositionExecutive Vice President of Clinical DevelopmentColleagues
- JJJohn J. AlamCo-Founder, CEO, President & Director
- JSJoshua S. BogerIndependent Chair of the Board
- SLSylvie L. GregoireCo-Founder & Director
- WRWilliam Robert ElderCFO, General Counsel & Corporate Secretary
- MVMarinus VerwijsExecutive Vice President of Technical Operations
- JVJeffrey V. PoultonIndependent Director
- FEFrank E. ZavrlIndependent Director
